Device Groups Propose "Two-Tier" PS As Least Burdensome Alternative

FDA should require device manufacturers to conduct targeted postmarket studies only if specific problems arise during routine monitoring, the American Society for Quality says in Nov. 27 comments to the agency on a proposed rule for postmarket surveillance (PS).